The new issue of Oxurion's annual magazine is here! Perspectives Magazine 2020 features Patrik De Haes, M.D., CEO and Thomas Clay, Chairman of the board, looking back on a transformational and important year and interviews with key opinion leaders like Arshad Khanani, M.D., M.A., Pravin Dugel, M.D., and professor Alan Stitt of Queen's University in Belfast.
Two clinical phase 1 studies in DME delivered excellent results.
Pravin Dugel, M.D., describes why plasma kallikrein (PKal) may be a viable target for the treatment of DME. As Dr. Dugel explains, THR-149 is a potent, reversible peptide inhibitor designed to target PKal.
Arshad Khanani, M.D., explains integrin antagonism as a model for therapeutic treatment, and summarizes the structure and results of a phase 1 dose-escalation study that evaluated the safety of THR-687 in patients with DME. Efficacy results from the study are also reviewed.
Discover our storiesRead Perspectives magazine online
Perspective Magazine 2020 reflects our efforts and features our partners, NGO’s, patient organizations, our own team members and professionals from the eye community.